Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak

J Allergy Clin Immunol Pract. 2020 Sep;8(8):2790-2792.e1. doi: 10.1016/j.jaip.2020.06.041. Epub 2020 Jun 29.

Authors

Edoardo Savarino¹, Greta Lorenzon², Matteo Ghisa², Giorgio Laserra², Brigida Barberio², Daria Maniero², Vincenzo Savarino³, Fabiana Zingone²

Affiliations

¹ Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. Electronic address: edoardo.savarino@unipd.it.
² Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
³ Department of Internal Medicine and Mediacal Specialties, University of Genoa, Genoa, Italy.

No abstract available

Publication types

Observational Study

MeSH terms

Adolescent
Adrenal Cortex Hormones / therapeutic use
Adult
Aged
Aged, 80 and over
Betacoronavirus
Body Mass Index
COVID-19
Case-Control Studies
Child
Coronavirus Infections / epidemiology*
Coronavirus Infections / physiopathology
Diet, Gluten-Free
Eosinophilia / drug therapy
Eosinophilia / epidemiology*
Female
Gastrointestinal Diseases / drug therapy
Gastrointestinal Diseases / epidemiology*
Humans
Male
Middle Aged
Pandemics
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / physiopathology
Prospective Studies
Proton Pump Inhibitors / therapeutic use
SARS-CoV-2
Young Adult

Substances

Adrenal Cortex Hormones
Proton Pump Inhibitors